Page last updated: 2024-08-24

irinotecan and sesquiterpenes

irinotecan has been researched along with sesquiterpenes in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's3 (50.00)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujimoto, M; Fujiwara, M; Hasegawa, S; Ishikawa, H; Kamma, H; Ohtsuka, M; Satoh, H; Yamashita, YT; Yazawa, T1
Britten, CD; Eckhardt, SG; Hilsenbeck, SG; MacDonald, JR; Mangold, G; Marty, J; Rowinsky, EK; Von Hoff, DD; Weitman, S1
Billups, C; Bjornsti, MA; Houghton, PJ; Liang, H; Peterson, JK; Woo, MH1
Lokiec, F; RezaĆ­, K; Urien, S1
Liang, H1
Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ1

Trials

2 trial(s) available for irinotecan and sesquiterpenes

ArticleYear
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
    Journal of pharmacokinetics and pharmacodynamics, 2005, Volume: 32, Issue:5-6

    Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Humans; Irinotecan; Middle Aged; Models, Biological; Molecular Structure; Neoplasm Metastasis; Neoplasms; Prodrugs; Sesquiterpenes

2005
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cinnamates; Colorectal Neoplasms; Cyclohexanes; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epoxy Compounds; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Models, Statistical; Oxaloacetates; Republic of Korea; Sesquiterpenes; Survival Analysis; Treatment Failure

2012

Other Studies

4 other study(ies) available for irinotecan and sesquiterpenes

ArticleYear
Angiocytotoxic therapy in human non-small cell lung cancer cell lines--advantage of combined effects of TNP-470 and SN-38.
    Acta oncologica (Stockholm, Sweden), 1998, Volume: 37, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cyclohexanes; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Irinotecan; Lung Neoplasms; O-(Chloroacetylcarbamoyl)fumagillol; Sesquiterpenes; Tumor Cells, Cultured

1998
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Cancer research, 1999, Mar-01, Volume: 59, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Sesquiterpenes; Transplantation, Heterologous

1999
Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
    Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Female; Irinotecan; Mice; Mice, Inbred ICR; Sesquiterpenes; Treatment Failure; Xenograft Model Antitumor Assays

2005
Comparison of antitumor activities in tumor xenograft treatment.
    Contemporary clinical trials, 2007, Volume: 28, Issue:2

    Topics: Algorithms; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease Models, Animal; Humans; Irinotecan; Mice; Sesquiterpenes; Transplantation, Heterologous; Treatment Outcome

2007